Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 8/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249231 | 0.92 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3ATMAKR1C3 | |
| SCHEMBL20249225 | 0.92 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3ATMAKR1C3 | |
| SCHEMBL18291586 | 0.83 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3ATMAKR1C3 | |
| SCHEMBL20038339 | 0.82 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3ATMAKR1C3 | |
| SCHEMBL20255396 | 0.80 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3ATMAKR1C3 | |
| SCHEMBL20249361 | 0.78 | SIGMAR1 (0.33) | SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL20249262 | 0.77 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3AKR1C3 | |
| SCHEMBL20249312 | 0.77 | PIM1 (0.38) | AKR1C3 | |
| SCHEMBL20249438 | 0.77 | IDH1 (0.32) | SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL20249454 | 0.77 | IDH1 (0.32) | SLC6A2SLC6A4SLC6A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | SLC6A2 2659/4885SLC6A4 1825/4885SLC6A3 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.